Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Sensorium Therapeutics is raising $24,789,809.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Dick Simon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Sensorium Therapeutics
Sensorium Therapeutics is dedicated to enhancing mental well-being and improving the human experience at scale. Sensoriums programs and platforms leverage ethnobotanically derived compounds to better understand the brain and accelerate the development of novel therapeutics across a broad set of psychiatric and neurological disorders.

To learn more about Sensorium Therapeutics, visit http://www.sensorium.bio/

Contact:
Dick Simon, Chief Executive Officer
562-688-5433
https://www.linkedin.com/in/dick-simon-6050ba5/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved